Belvedere Trading
CBAY

Belvedere Trading’s Cymabay Therapeutics CBAY Stock Holding History

Belvedere Trading’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,800
Closed -$414K – 1052
2023
Q3 		$414K Buy
+27,800
New +$369K ﹤0.01% 134
2023
Q1 		– Sell
-14,500
Closed -$90.9K – 1560
2022
Q4 		$90.9K Buy
+14,500
New +$55.1K ﹤0.01% 496

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Belvedere Trading's CBAY Position: Q4 2023 in Review

Belvedere Trading sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 2,051 shares — an estimated $30.6K sold.

Belvedere Trading first reported a position in CBAY in Q4 2022 and held it in 2 quarters. The position peaked at $30.6K in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Belvedere Trading reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Belvedere Trading sold 2,051 Cymabay Therapeutics shares in Q4 2023, an estimated $30.6K.
  • Belvedere Trading first reported a position in Cymabay Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belvedere Trading's Cymabay Therapeutics position peaked at $30.6K in Q3 2023.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Belvedere Trading's 13F filing for Q4 2023, filed 13 Feb 2024.